Firmonertinib

Firmonertinib is an oral, brain-penetrant, mutant-selective inhibitor of EGFR. It targets a broad spectrum of EGFR mutations, including exon 20 insertions and the T790M resistance mutation. Firmonertinib is being developed as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions.